Castagnola vs Efstathiou
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Best | Volume | Azuro | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|---|
Luca Castagnola Winner | 99.0%Kalshi | $940.5K | — | — | — | — | No liquidity50.0% | — | |
Melios Efstathiou | 1.0%Kalshi | $670.8K | — | — | — | — | No liquidity50.0% | — |
AI-generated summary, may be inaccurate.
This market covers a quarterfinal clash between Luca Castagnola and Melios Efstathiou at the ITF M15 Nova Gorica men's tournament, played on clay. The question is simply which player advances to the next round. The ITF Men's World Tennis Tour is the 2026 edition of the second-tier tour for men's professional tennis, organised by the ITF and sitting a level below the ATP Challenger Tour. Kalshi is the dominant platform here, accounting for virtually all of the roughly $1.06 million in total volume, with $418,625 in liquidity. Polymarket lists the match but has recorded zero trading volume and just $63 in liquidity, leaving its prices stuck at a flat 50.0% for each player — a default that carries no informational weight. Kalshi's pricing is the only meaningful signal: Efstathiou is the favourite at 56.0% implied probability, with Castagnola trailing at 45.0%. The margin is modest — roughly 11 percentage points — reflecting genuine uncertainty in a match between two lower-ranked professionals. Efstathiou is a Cypriot player whose career-high ATP singles ranking of No. 667 was achieved on 4 May 2026, with a career-high doubles ranking of No. 464 reached in November 2025. His most recent result prior to this event was a win over Nikita Mashtakov in ITF M15 Heraklion 6. The cross-platform picture is straightforward: Polymarket's 50/50 split is purely a liquidity artefact, and Kalshi's deep, well-traded market is the only reliable gauge of sentiment — placing Efstathiou as a slim but clear favourite heading into this clay-court quarterfinal.
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.